A Retatrutide 4mg dose is a piece of research context worth raising with a provider, not a figure to pursue on ones own
It is the active pharmaceutical ingredient in Novo Nordisks Ozempic (FDA-approved 2017 for Type 2 diabetes), Wegovy (FDA-approved 2021 for chronic weight management in adults with obesity, and 2024 expanded for cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease), and Rybelsus (oral form, Type 2 diabetes)
One change that some people notice while taking semaglutide is yellow-colored stool
But the theory is supported by basic receptor pharmacology principles that apply across all G protein-coupled receptors
These findings suggest that the sensitive populations for immunotherapy in the neoadjuvant setting may differ between HR+ and TNBC patients
The degree of this effect varies between individuals based on semaglutide dose, duration of therapy, and your genetic predisposition to peptide sensitivity